Phase 3 N=249 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Adult Kidney Wilms Tumor · Beckwith-Wiedemann Syndrome · Childhood Kidney Wilms Tumor
Primary: Event-Free Survival (EFS) — 0.82 Probability
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=808 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Stage I Kidney Wilms Tumor · Stage II Kidney Wilms Tumor · Stage III Kidney Wilms Tumor
Primary: Event Free Survival Probability — 0.88; 0.87; 0.88 Probability
Phase 3 N=380 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Stage III Kidney Wilms Tumor · Stage IV Kidney Wilms Tumor
Primary: Event Free Survival Probability — 0.79 Probability
Phase 2 N=291 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Childhood Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma · Clear Cell Sarcoma of the Kidney
Primary: Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT) — 76.1; 25.0; 87.5 Percentage of 4-year OS — p=.0199
N/A N=31 Radiosurgery in Treating Patients With Kidney Tumors
Kidney Cancer
Primary: Maximum Tolerated Dose of Radiosurgery — 48; 60 Gy
Phase 2 N=9 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
Phase 3 N=78 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Phase 2 N=102 BMS 247550 to Treat Kidney Cancer
Renal Cell Carcinoma
Primary: Response Rate — 1; 9.4; 12.6; 76.8 Percentage of participants
Phase 2 N=21 Neoadjuvant Pazopanib in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Response Rate — 8 Participants
N/A N=26 Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
Kidney Cancer
Primary: Safety of Sunitinib Malate (SM) — .350 proportion of participants
Phase 2 N=30 Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
Kidney Cancer
Primary: Response to Sunitinib Therapy — 13 participants
Phase 2 N=19 Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Kidney Cancer
Primary: Progression-free Survival at 3 Months — 2.9 months
Phase 3 N=1,499 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Kidney Cancer
Primary: 5-year Recurrence-free Survival (RFS) — 63; 67 percentage of paticipants
Phase 2 N=62 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Neurofibromatosis Type 1
Primary: Time to Disease Progression Based on Volumetric MRI — 15.4 Months
Phase 2 N=37 Phase II Study of Vandetanib in Individuals With Kidney Cancer
Renal Cancer · Von Hippel Lindau
Primary: Overall Response Rate. — 3; 0; 75; 0 percentage of participants
Phase 2 N=10 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Overall Efficacy, Taking Into Account Both Objective Response and Meaningful Reductions in Tumor Burden That do Not Meet the RECIST Criteria for PR or CR (e.g., 5-30%…
Phase 3 N=226 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Renal Cell Carcinoma · Kidney Cancer
Primary: Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT. — 0.76; 0.86; 0.86; 0.47 Proportion of participants — p=0.023
Phase 2 N=13 Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
Renal Cell Carcinoma · Graft-Versus-Host Disease · Engraftment Syndrome
Primary: Clinical Regression of Metastatic Renal Cell Carcinoma (Partial Response (PR)) or Complete Remission of Tumor (Complete Response (CR)) — 0; 0; 8; 1 participants
Phase 2 N=20 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Childhood Hepatocellular Carcinoma · Papillary Thyroid Cancer · Previously Treated Childhood Rhabdomyosarcoma
Primary: Objective Response by RECIST Criteria v 1.1 — 10; 10; 0; 0 participants
Phase 2 N=19 Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Phase 2 N=25 Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Clear Cell Renal Cell Carcinoma · Stage I Renal Cell Cancer · Stage II Renal Cell Cancer
Primary: Number of Participants Who Could Undergo Partial Nephrectomy After Pazopanib Therapy — 6 Participants
Phase 2 N=64 Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Phase 2 N=28 Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria — 14; 7; 4 Participants
Phase 2 N=92 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
Carcinoma · Renal Cell · Non Clear Cell Renal Carcinoma
Primary: To Evaluate Efficacy of RAD001 as Monotherapy for the Treatment of Papillary Renal Cancer. Efficacy is Defined as the Percentage of Patients Progression-free at 6…
Phase 2 N=9 Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
GIST
Primary: Number of Participants With a Clinical Activity-radiographic Response — 0; 0; 0; 0 Participants
N/A N=20 The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy
Renal Cancer · Tumor, Solid · Kidney Cancer
Primary: Primary Effectiveness: Technical Success — 100.0 percentage of tumors
Phase 2 N=69 Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
Chromophobe Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma · Papillary Renal Cell Carcinoma
Primary: Maximum Tolerated Dose (MTD) of BAY 43-9006 (Sorafenib)in Combination With Bevacizumab (Phase I) — 200 mg
Phase 1 N=26 Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Cancer of Kidney · Kidney Cancer · Renal Cancer
Primary: Positive Predictive Value (PPV) of 124I-cG250 Based on Positron-Emission Tomography/Computed Tomography (PET/CT) Imaging in the Detection of Clear Cell Renal Cell…
Phase 2 N=73 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Advanced and Metastatic Silent Neuro-Endocrine Tumors · Carcinoma · Neuroendocrine
Primary: Percentage of Participants' Best Overall Response Rate at 12 Months - Per Protocol Set (PP) — 0.0; 0.0; 56.7; 43.3 percentage of participants
Phase 2 N=45 Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
Neurofibromatosis Type 1 · Plexiform Neurofibroma
Primary: Change From Baseline Target Tumor Volume at 12 Months — 27; 17 Participants